At Halol Facility
Sun Pharmaceutical Industries has informed that the US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited's Halol facility (Gujarat, India) from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483, with 8 observations.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
